Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-11 PET/CT for Screening Prior to 177Lu-PSMA-617 Therapy
NCT05547386Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of gallium ga-68 gozetotide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Mayo Clinic. Started May 2022; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05547386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547386.